“A good question for the next Q&A would be to ask who’s writing our PRs, and whether NP can see how any ambiguity gets exploited by shorts.

But Evil, someone really wants to know if CYDY is buying Incelldx and they’ll ask it 10x times, so your legitimate question will likely not get answered. Oh, also ahead of you in the question que is, “How is leronlimab different from Remdesevir?” Sorry.

Seriously, cut funding to Proactiv and redirect the funds to a PR firm.